How Rezdiffra Works Against Liver Disease
Rezdiffra (resmetirom) treats noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis by activating thyroid hormone receptor beta (THR-β) in the liver. This reduces liver fat buildup, slows fibrosis progression, and resolves NASH without worsening scarring. It's the first FDA-approved drug specifically for this NASH stage, targeting adults unable to lose at least 10% body weight after lifestyle changes.[1][2]
What Is Rezdiffra Targeting Exactly?
NASH involves excess fat, inflammation, and fibrosis in the liver, often from metabolic issues like obesity or diabetes. Rezdiffra mimics thyroid hormone effects selectively in liver cells via THR-β activation, boosting fat metabolism (lipolysis) and decreasing new fat production (lipogenesis). Clinical trials showed 25-30% of patients achieving NASH resolution and 25% seeing fibrosis improvement after one year, versus placebo.[3]
How Is It Given and What Results from Trials?
Patients take 80-100 mg oral tablets daily with food. In the MAESTRO-NASH phase 3 trial, 372 patients on 100 mg saw statistically significant NASH resolution (26% vs. 10% placebo) and fibrosis reduction (24% vs. 15%), with sustained effects at 52 weeks. Liver enzymes like ALT dropped, and no worsening of fibrosis occurred.[1][4]
Common Side Effects Patients Experience
Diarrhea (25-30%), nausea (15-20%), and abdominal pain affect many users initially but often ease. Rare risks include gallbladder issues (3-5%) or drug interactions with statins. Monitoring liver function is standard.[2]
Who Makes Rezdiffra and When Can Generics Arrive?
Madrigal Pharmaceuticals developed and markets it, approved by FDA in March 2024. Patents listed on DrugPatentWatch.com extend protection until at least 2036, with challenges possible but none resolved yet. No generics expected soon.[5][6]
How Does It Stack Up Against Other NASH Treatments?
No other NASH-specific drugs exist; alternatives like semaglutide (GLP-1 agonists) aid weight loss indirectly but lack direct fibrosis data. Rezdiffra pairs well with them. Obeticholic acid failed FDA approval due to risks.[3]
Sources
[1]: FDA Label for Rezdiffra
[2]: Madrigal Pharmaceuticals - Rezdiffra Overview
[3]: NEJM - MAESTRO-NASH Trial
[4]: ClinicalTrials.gov - MAESTRO-NASH
[5]: DrugPatentWatch.com - Resmetirom Patents
[6]: FDA Orange Book - Rezdiffra Exclusivity